Open Research Newcastle
Browse

Key opinion leaders: independent experts or drug representatives in disguise?

Download (168.62 kB)
journal contribution
posted on 2025-05-11, 18:41 authored by Ray Moynihan
In the world of medicine, “key opinion leader” is the somewhat Orwellian term used to describe the senior doctors who help drug companies sell drugs. These influential doctors are engaged by industry to advise on marketing and help boost sales of new medicines. Like drug marketing strategies, the use of key opinion leaders is a global phenomenon. In an article for UK based Pharmaceutical Marketing magazine describing the “tricks of the trade,” drug company marketing staff are urged to work routinely with key opinion leaders and try to make them into “product champions.” Importantly, marketing staff should find doctors who will endorse their products, “who may be further down the influence ladder,” and then help “raise their profile, and so develop them into opinion leaders.” Former sales representative Ms Elliott says drug companies desperately need key opinion leaders. “There are a lot of physicians who don’t believe what we as drug representatives say. If we have a KOL [key opinion leader] stand in front of them and say the same thing, they believe it." If industry’s sponsorship of medical education is wound back, it is possible that more independent sources of funding will be secured. Yet if the speakers giving the educational presentations in any newly independent forums continue to be the overpaid “thought leaders” on the drug company payrolls, little, if anything, will have been gained.

History

Journal title

British Medical Journal

Volume

336

Pagination

1402-1403

Publisher

BMJ Publishing Group

Language

  • en, English

College/Research Centre

Faculty of Health

School

School of Medicine and Public Health

Usage metrics

    Publications

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC